Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In Women With A

		HER2 Support Group Forums > Breast Cancer Newsfeed
Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In Women With A

12-11-2012, 03:20 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,946	Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In Women With A SAN ANTONIO - The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)... More...

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Forum Rules

All times are GMT -7. The time now is 01:30 PM.